Angiotensin-converting enzyme 2 in human plasma and lung tissue
Angiotensin-converting enzyme 2 in human plasma and lung tissue
复制标题
DOI：
10.1080/08037051.2022.2154745
复制
发表时间：
2022-12
期刊：
影响因子：
1.8
通讯作者：
Jing Xie;Qi-Fang Huang;Zhihan Zhang;Y. Dong;Haimin Xu;Yanan Cao;C. Sheng;Yan Li;Chaofu Wang;Xuefeng Wang;Ji-Guang Wang
中科院分区：
文献类型：
--
作者：
Jing Xie;Qi-Fang Huang;Zhihan Zhang;Y. Dong;Haimin Xu;Yanan Cao;C. Sheng;Yan Li;Chaofu Wang;Xuefeng Wang;Ji-Guang Wang
摘要目的研究肺外科手术患者血浆血管紧张素转换酶2 （ACE2）的浓度，并用二氨基联苯胺平均浓度测定ACE2在肺组织中的表达。材料与方法研究对象从上海郊区某居民区进行血浆ACE2浓度研究（n = 503），随机从瑞金医院储存的肺组织样本（男性80例，女性78例）中选取肺组织样本。结果在校正协变量的分析中，男性的血浆ACE2浓度（1.21 vs. 0.98 ng/mL, p = 0.027）和肺组织中ACE2的平均强度（55.1 vs. 53.9 a.u, p = 0.037）显著高于女性。随着年龄的增长，血浆中ACE2浓度降低（p = 0.001），肺组织中ACE2平均强度有升高的趋势（p = 0.087）。高血压患者血浆中ACE2浓度高于血压正常者，尤其是高血压患者（1.23 vs. 0.98 ng/mL, p = 0.029 vs.血压正常者），RAS抑制剂使用者与其他类降压药使用者之间无显著差异（p = 0.64）。服用和未服用RAS抑制剂的患者肺组织中ACE2的平均强度差异无统计学意义（p = 0.14）。正常血糖和糖尿病患者血浆中ACE2浓度和肺组织中ACE2的平均强度均无差异（p≥0.20）。结论血浆和肺组织中ACE2根据患者的几个主要特征表现出不同的变化。上下文是什么？•ACE2的主要生理功能是将血管紧张素I和II分别降解为血管紧张素1-9和1-7。•ACE2被发现是严重急性呼吸综合征冠状病毒（SARS）感染的中介。•关于ACE2在人体中的研究很少，尤其是在肺组织中的研究。•在本报告中，我们分别在两个研究人群中研究了血浆中ACE2浓度和用二氨基联苯胺平均强度定量测定的肺组织中ACE2的表达。有什么新鲜事吗？•我们的研究调查了人类受试者的循环和组织ACE2。主要发现是：•在男性和女性中，年轻参与者的血浆ACE2浓度高于年长参与者，而肺组织中ACE2的平均强度随着年龄的增长而增加。•与血压正常者相比，高血压患者血浆中ACE2浓度较高，但肺组织中ACE2的平均强度相似。•血浆ACE2浓度和肺组织ACE2表达在RAS抑制剂使用者和其他类抗高血压药物使用者之间均无显著差异。影响是什么？•血浆和肺组织中的ACE2根据性别、年龄、高血压治疗和未治疗等几个主要特征表现出不同的变化。•一个主要的含义是血浆ACE2浓度可能不是肺组织中ACE2表达的合适替代品，因此不是SARS-COV-2感染或死亡的良好预测指标。
Abstract Purpose We investigated plasma angiotensin-converting enzyme 2 (ACE2) concentration in a population sample and the ACE2 expression quantitated with the diaminobenzidine mean intensity in the lung tissue in patients who underwent lung surgery. Materials and methods The study participants were recruited from a residential area in the suburb of Shanghai for the plasma ACE2 concentration study (n = 503) and the lung tissue samples were randomly selected from the storage in Ruijin Hospital (80 men and 78 age-matched women). Results In analyses adjusted for covariables, men had a significantly higher plasma ACE2 concentration (1.21 vs. 0.98 ng/mL, p = 0.027) and the mean intensity of ACE2 in the lung tissue (55.1 vs. 53.9 a.u., p = 0.037) than women. With age increasing, plasma ACE2 concentration decreased (p = 0.001), while the mean intensity of ACE2 in the lung tissue tended to increase (p = 0.087). Plasma ACE2 concentration was higher in hypertension than normotension, especially treated hypertension (1.23 vs. 0.98 ng/mL, p = 0.029 vs. normotension), with no significant difference between users of RAS inhibitors and other classes of antihypertensive drugs (p = 0.64). There was no significance of the mean intensity of ACE2 in the lung tissue between patients taking and those not taking RAS inhibitors (p = 0.14). Neither plasma ACE2 concentration nor the mean intensity of ACE2 in the lung tissue differed between normoglycemia and diabetes (p ≥ 0.20). Conclusion ACE2 in the plasma and lung tissue showed divergent changes according to several major characteristics of patients. Plain language summary What is the context? • The primary physiological function of ACE2 is the degradation of angiotensin I and II to angiotensin 1-9 and 1-7, respectively. • ACE2 was found to behave as a mediator of the severe acute respiratory syndrome coronavirus (SARS) infection. • There is little research on ACE2 in humans, especially in the lung tissue. • In the present report, we investigated plasma ACE2 concentration and the ACE2 expression quantitated with the diaminobenzidine mean intensity in the lung tissue respectively in two study populations. What is new? • Our study investigated both circulating and tissue ACE2 in human subjects. The main findings were: • In men as well as women, plasma ACE2 concentration was higher in younger than older participants, whereas the mean intensity of ACE2 in the lung tissue increase with age increasing. • Compared with normotension, hypertensive patients had higher plasma ACE2 concentration but similar mean intensity of ACE2 in the lung tissue. • Neither plasma ACE2 concentration nor lung tissue ACE2 expression significantly differed between users of RAS inhibitors and other classes of antihypertensive drugs. What is the impact? • ACE2 in the plasma and lung tissue showed divergent changes according to several major characteristics, such as sex, age, and treated and untreated hypertension. • A major implication is that plasma ACE2 concentration might not be an appropriate surrogate for the ACE2 expression in the lung tissue, and hence not a good predictor of SARS-COV-2 infection or fatality.